Hanmi Pharmaceutical Co., Ltd. · KRX:128940

Hanmi Pharmaceutical — ASPEN 2021 Nutrition Science & Practice Conference

20 slides from Hanmi Pharmaceutical's conference presentation, 2021

  1. Slide 1: ASPEN 2021 Nutrition Science & Practice Conference

    ASPEN 2021 Nutrition Science & Practice Conference Intestinotrophic effect of a novel long-acting GLP-2 analog, HM15912, in animal model for short bowel syndrome and potential as monthly administration Jae Hyuk Choi, Jin Bong Lee, Eun Jin Park, Sung Min Bae, Dae Jin Kim, Young Hoon Kim, In Young Cho

  2. Slide 2: Disclosures

    © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. Employee of Hanmi Pharm. Co., Ltd. Disclosures

  3. Slide 3: What GLP-2 is

    What GLP-2 is Proglucagon 33 amino acids Various biological actions Glicentin GLP-1 IP2 GLP-2 ↓ Food intake GRPP OXM © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. ↓ Bone resorption ↓ Gastric motility & secretion Intestinal L cell ↑ Energy absorption & muc

  4. Slide 4: What GLP-2 is

    What GLP-2 is Proglucagon 33 amino acids Various biological actions Glicentin GLP-1 IP2 GLP-2 ↓ Food intake GRPP OXM © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. ↓ Bone resorption ↓ Gastric motility & “Crypt cell proliferation via GLP-2/IGF-1 axis” secre

  5. Slide 5: Treatment goal of Short bowel syndrome and benefits of GLP-2 therapy

    Treatment goal of Short bowel syndrome and benefits of GLP-2 therapy Normal bowel SBS SBS (Length <150 cm) + GLP-2 therapy Patients on IV nutrition Suffer from malnutrition, liver failure, sepsis Especially, 50% of pediatric patients died ≤ age 3 GLP-2 receptor agonist is ideal therapy © 2021 ASPEN

  6. Slide 6: Treatment goal of Short bowel syndrome and benefits of GLP-2 therapy

    Treatment goal of Short bowel syndrome and benefits of GLP-2 therapy Normal bowel SBS SBS (Length <150 cm) + GLP-2 therapy Patients on IV nutrition Suffer from malnutrition, liver failure, sepsis Especially, 50% of pediatric patients died ≤ age 3 GLP-2 receptor agonist is ideal therapy © 2021 ASPEN

  7. Slide 7: What a long-acting GLP-2 analog is

    What a long-acting GLP-2 analog is Hanmi’s GLP-2 analog (HM15912) is conjugated with a Potent GLP-2 human IgG4 Fc fragment via flexible linker analog © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. Flexible PEG Linker [General profile] • Rationally designed

  8. Slide 8: Potent intrinsic activity and high sequence homology with human GLP-2

    Potent intrinsic activity and high sequence homology with human GLP-2 Human GLP-2 120 Teduglutide 100 3-fold more potent GLP-2 analog (Peptide moiety) © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. vs human GLP-2 80 HM15912 60 40 Due to the flexible linker

  9. Slide 9: Pharmacokinetics in rodent

    Pharmacokinetics in rodent © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. t1/2= 42.3 h t1/2= 0.6 h Materials Dose-normalized AUC (ng*hr/mL per μg/kg) Teduglutide 1.0 HM15912 283.3

  10. Slide 10: Hypothesis & study methods

    Hypothesis & study methods HM15912, long-acting GLP-2 analog, is desired to have therapeutic potential for short bowel syndrome with significant efficacy Presentation Purpose Species / Strain Induction method No. © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserv

  11. Slide 11: Hypothesis & study methods

    Hypothesis & study methods HM15912, long-acting GLP-2 analog, is desired to have therapeutic potential for short bowel syndrome with significant efficacy Presentation Purpose Species / Strain Induction method No. © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserv

  12. Slide 12: Intestinotrophic efficacy in SBS model rats

    Intestinotrophic efficacy in SBS model rats Experimental design Operation Drug treatment 2 weeks -1 0 13 SBS rat Necropsy © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. (n=9, 80% intestinal resection)

  13. Slide 13: Intestinotrophic efficacy in SBS model rats

    Intestinotrophic efficacy in SBS model rats Experimental design Operation Drug treatment 2 weeks -1 0 13 SBS rat Necropsy © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. (n=9, 80% intestinal resection) Weight of Jejunum (Physical improvement) ■ Non-operatio

  14. Slide 14: Intestinotrophic efficacy in SBS model rats: D-xylose absorption

    Intestinotrophic efficacy in SBS model rats Experimental design Operation Drug treatment 2 weeks -1 0 13 SBS rat Necropsy © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. (n=9, 80% intestinal resection) Weight of Jejunum (Physical improvement) D-Xylose absor

  15. Slide 15: Mucosal area and crypt depth in jejunum

    Intestinotrophic efficacy in SBS model rats Experimental design Operation Drug treatment 2 weeks -1 0 13 SBS rat Necropsy © 2021 ASPEN | American Society for Parenteral and Enteral Nutrition. All Rights Reserved. (n=9, 80% intestinal resection) Non-operation Sham-operation Resection vehicle Villus h

  16. Slide 16: Intestinotrophic efficacy in the various dosing intervals

    Intestinotrophic efficacy in the various dosing intervals Experimental design ■ Teduglutide 0.2xHED, QD [Emax, EPAR] Drug treatment (Weekly, Bi-weekly, Monthly) ■ Apraglutide (Synthesized) ~10 mg/week HED Body weight ■ Glepaglutide (Synthesized) ~10 mg/week HED 2 weeks Small intestine mass □ HM15912

  17. Slide 17: Intestinotrophic efficacy in the various dosing intervals

    Intestinotrophic efficacy in the various dosing intervals Experimental design ■ Teduglutide 0.2xHED, QD [Emax, EPAR] Drug treatment (Weekly, Bi-weekly, Monthly) ■ Apraglutide (Synthesized) ~10 mg/week HED Body weight ■ Glepaglutide (Synthesized) ~10 mg/week HED 2 weeks Small intestine mass □ HM15912

  18. Slide 18: Intestinotrophic efficacy in the various dosing intervals

    Intestinotrophic efficacy in the various dosing intervals Experimental design ■ Teduglutide 0.2xHED, QD [Emax, EPAR] Drug treatment (Weekly, Bi-weekly, Monthly) ■ Apraglutide (Synthesized) ~10 mg/week HED Body weight ■ Glepaglutide (Synthesized) ~10 mg/week HED 2 weeks Small intestine mass □ HM15912

  19. Slide 19: Executive summary

    Contact information: jaehyuk.choi@hanmi.co.kr Executive summary • Maximize remnant intestinal absorptive capacity and wean off PN, has become the focus and breakthrough point of SBS treatment. For this, teduglutide was firstly approved based on its intestinotrophic effect • The only approved GLP-2 d

  20. Slide 20: References

    References 1. Drucker, DJ.; Erlich, P.; Asa, SL.; Brubaker, PL. Induction of intestinal epithelial proliferation by glucagon- like peptide 2. Proc Natl Acad Sci USA. 1996, 93(15), 7911-7916. 2. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal

Hanmi Pharmaceutical — ASPEN 2021 Nutrition Science & Practice Conference on 6ix